Statements
Members
Dr Lawson Ahadzie
Former Head of Surveillance Department, Ghana Health Service/Ministry of Health, Accra, Ghana
Mr André Basse
Counsellor, Embassy of Senegal, Paris, France
Dr Muhammad Akbar Chaudhry
Principal, Professor of Medicine, Fatima Jinnah Medical College, Lahore, Pakistan
Senior Expert in Disease Control
Dr Nancy Cox
Director, Influenza Division, Centers for Disease Control and Prevention, Atlanta, USA
Dr Anthony Evand
Chief, Aviation Medicine Section, International Civil Aviation Organization, Montreal, Canada
Emeritus Professor, Curtin University, Perth, Australia
Professor Arnold Monto
Professor, Department of Epidemiology, University of Michigan, Ann Arbor, USA
Dr Fernando Otaiza
Coordinator, National Infection Control Program, Ministry of Health, Santiago, Chile
Dr Rogelio Pérez Padilla
Director General, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico City, Mexico
Dr Masato Tashiro
Director, Department of Viral Diseases and Vaccine Control, National Institute of Infectious Diseases, Tokyo, Japan
Dr Claude Thibeault
Consultant in Aviation Medicine and Occupational Health, Montreal, Canada
Dr John Wood
Principal Scientist, Division of Virology, National Institute for Biological Standards and Control, Herts, United Kingdom
Head of Influenza, Respiratory Virology & Polio Reference Services, UK Health Security Agency; Co-Director, Health Protection Research Unit in Respiratory Infections, NIHCR, Imperial College London, UK
Advisor to the Emergency Committee
Professor Neil M. Ferguson
MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom
Declaration of Interests
Dr Nancy Cox
Her public health and surveillance research unit at the US Centers for Disease Control & Prevention (CDC) receives financial support from IFPMA for activities of CDC as a WHO Collaborating Centre in the field of influenza vaccine research and virus isolation work.
Professor Arnold Monto
He has declared current and past consultancies in the field of pandemic and/or seasonal influenza for GSK, Novartis, Roche, Baxter and Sanofi. The remuneration for each of these consultancies is below US$10 000. In addition, his research unit at the University of Michigan has received a grant from Sanofi Pasteur for a clinical trial conducted in 2007-2008 on the comparative efficacy of inactivated and live attenuated influenza vaccines.
Dr Claude Thibeault
Since 2004, he is the Consultant Medical Advisor to International Air Transport Association.
Dr John Wood
His research unit at the National Institute for Biological Standards and Control (NIBSC), a centre of the UK Health Protection Agency, has performed contract research for Sanofi Pasteur, CSL, IFPMA, Novartis and Powdermed in the field of influenza vaccine research and development.
Professor Maria Zambon
The UK Health Protection Agency Centre for Infection receives funding from vaccine manufacturers, including Sanofi, Novartis, CSL, Baxter and GSK, for contract work in Dr Zambon's laboratory.
Professor Neil M. Ferguson (Advisor)
He has acted as a consultant for Roche, Novartis and GSK Biologicals (ceasing in 2007), with total remuneration from all such work being under US$7 000 in 2007.
The interests summarized above do not give rise to a conflict of interest such that the experts concerned should be partially or totally excluded from participation in the Emergency Committee. However, following WHO's policy, they were disclosed within the Committee so that other members were aware of them. All other Members of the Emergency Committee declared no relevant interests.
*This document has been updated to reflect revisions in the summary of interests and affiliation information of Professor Neil M. Ferguson based upon additional information received from him after initial confirmation and publication of this List.